单核细胞HLA-DR表达与大B细胞淋巴瘤抗CD19 CAR-T细胞治疗结局的关系
在103例复发/难治性大B细胞淋巴瘤患者中,评估抗CD19 CAR-T输注前后单核细胞HLA-DR表达的变化及其与不良事件和治疗反应的关系。D-7时单核细胞HLA-DR低(<13500抗体/细胞)与较差缓解持续时间和生存相关。
要点
- CAR-T输注前D-7单核细胞HLA-DR低(<13500抗体/细胞)与较差缓解持续时间和生存相关。
- 低单核细胞HLA-DR组托珠单抗使用更频繁。
核心结论
- 淋巴细胞清除前以单核细胞HLA-DR下调为特征的单核细胞失调,与炎症和免疫抑制性肿瘤环境相关,并与复发/难治性大B细胞淋巴瘤患者抗CD19 CAR-T细胞治疗失败相关。
- 调节这些髓系细胞是改善CAR治疗的有前景领域。
研究设计与样本
- 在103例复发/难治性大B细胞淋巴瘤患者中,评估商业化抗CD19 CAR-T细胞输注前后单核细胞HLA-DR表达的变化及其与不良事件和治疗反应的关系。
主要发现
- CAR-T输注前D-7单核细胞HLA-DR低(<13500抗体/细胞)与年龄较大、体能状态较差、肿瘤负荷较高和炎症标志物升高相关。
- 中位随访7.4个月,D-7单核细胞HLA-DR低的患者缓解持续时间和生存均差于D-7单核细胞HLA-DR较高组。
- 低单核细胞HLA-DR D-7组托珠单抗使用更频繁。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite their unprecedented success in relapsed/refractory (R/R) large B-cell lymphoma (LBCL), anti-CD19 CAR T cells are associated with significant toxicity, and more than half of patients relapse. As monocytes emerged as key players in CAR therapy, we sought to evaluate the evolution of HLA-DR expression on monocytes (mHLA-DR) before and after commercial anti-CD19 CAR T-cell infusion in a large cohort (n = 103) of patients with R/R LBCL and its association with adverse events and treatment response. Cy-Flu-based lymphodepletion (LD) upregulated mHLA-DR in 79% of the cases, whereas in 2l% of cases (15 patients), the mHLA-DR level decreased after LD, and this decrease was associated with poorer outcome. Low mHLA-DR at day minus 7 (D-7) (<13 500 antibodies per cell) before CAR T-cell infusion correlated with older age, poorer performance status, higher tumor burden, and elevated inflammatory markers. With a median follow-up of 7.4 months, patients with low mHLA-DR D-7 exhibited a poorer duration of response and survival than the higher mHLA-DR D-7 group. For toxicity management, tocilizumab was more frequently used in the low-mHLA-DR D-7 group. These data suggest that monocyte dysregulation before LD, characterized by the downregulation of mHLA-DR, correlates with an inflammatory and immunosuppressive tumor environment and is associated with failure of anti-CD19 CAR T cells in patients with R/R LBCL. Modulation of these myeloid cells represents a promising field for improving CAR therapy.
引用
- Bourbon E, Sesques P, Gossez M, et al. HLA-DR expression on monocytes and outcome of anti-CD19 CAR T-cell therapy for large B-cell lymphoma. Blood Adv. 2023. PMID: 35439292. doi:10.1182/bloodadvances.2021006563
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。